Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Aclaris Therapeutics, Inc. (ACRS) had Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number of 541.63 thousand shares as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber · last filed 2018-11-06
- 2018-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 541.63K shares.
- 2018-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 532.76K shares.
- 2018-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 595.26K shares.
- 2017-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 283.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number |
|---|---|
| 2018-09-30 | 541.63K shares 10-Q · filed 2018-11-06 |
| 2018-06-30 | 532.76K shares 10-Q · filed 2018-08-03 |
| 2018-03-31 | 595.26K shares 10-Q · filed 2018-05-08 |
| 2017-12-31 | 283.55K shares 10-Q · filed 2018-11-06 |
| 2017-09-30 | 294.33K shares 10-Q · filed 2017-11-07 |
| 2016-12-31 | 219.61K shares 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |